MX2021008263A - Métodos de tratamiento de afecciones relacionadas con el receptor s1p1. - Google Patents

Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.

Info

Publication number
MX2021008263A
MX2021008263A MX2021008263A MX2021008263A MX2021008263A MX 2021008263 A MX2021008263 A MX 2021008263A MX 2021008263 A MX2021008263 A MX 2021008263A MX 2021008263 A MX2021008263 A MX 2021008263A MX 2021008263 A MX2021008263 A MX 2021008263A
Authority
MX
Mexico
Prior art keywords
treatment
methods
receptor
conditions related
acid
Prior art date
Application number
MX2021008263A
Other languages
English (en)
Spanish (es)
Inventor
Snehal Naik
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69467760&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021008263(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MX2021008263A publication Critical patent/MX2021008263A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
MX2021008263A 2019-01-08 2020-01-08 Métodos de tratamiento de afecciones relacionadas con el receptor s1p1. MX2021008263A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962789937P 2019-01-08 2019-01-08
PCT/US2020/012783 WO2020146529A1 (en) 2019-01-08 2020-01-08 Methods of treating conditions related to the s1p1 receptor

Publications (1)

Publication Number Publication Date
MX2021008263A true MX2021008263A (es) 2021-10-13

Family

ID=69467760

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008263A MX2021008263A (es) 2019-01-08 2020-01-08 Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.

Country Status (9)

Country Link
US (1) US20220142977A1 (https=)
EP (1) EP3908276B1 (https=)
JP (1) JP2022516662A (https=)
CN (2) CN118976023A (https=)
AU (1) AU2020206700A1 (https=)
CA (1) CA3124701A1 (https=)
IL (1) IL284114A (https=)
MX (1) MX2021008263A (https=)
WO (1) WO2020146529A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201906876PA (en) 2010-01-27 2019-09-27 Arena Pharm Inc Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
MX386419B (es) 2015-01-06 2025-03-18 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
EP3939965A1 (en) 2015-06-22 2022-01-19 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
WO2018151834A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
ES2987794T3 (es) 2018-06-06 2024-11-18 Arena Pharm Inc Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
US20210386706A1 (en) * 2018-10-03 2021-12-16 Arena Pharmaceuticals, Inc. Methods for the treatment of scleroderma
US20220142977A1 (en) 2019-01-08 2022-05-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
WO2025177319A2 (en) * 2024-02-22 2025-08-28 Msn Laboratories Private Limited, R&D Center Solid state forms of L-Arginine, (3R)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopent[b]indole-3-acetate and processes for preparation thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA019252B1 (ru) 2008-07-23 2014-02-28 Арена Фармасьютикалз, Инк. ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ (1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ
SI2342205T1 (sl) * 2008-08-27 2016-09-30 Arena Pharmaceuticals, Inc. Substituirani triciklični kislinski derivati kot agonisti S1P1 receptorja, uporabni v zdravljenju avtoimunskih in vnetnih obolenj
SG10201906876PA (en) 2010-01-27 2019-09-27 Arena Pharm Inc Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
DK3311834T3 (da) * 2011-05-02 2026-04-20 Millennium Pharmaceuticals Inc Formulering til anti-alfa4beta7-antistof
MX386419B (es) * 2015-01-06 2025-03-18 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
JP6047203B2 (ja) * 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および／または治療のための宿主防御タンパク質（ｈｄｐ）模倣薬
US20220142977A1 (en) 2019-01-08 2022-05-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor

Also Published As

Publication number Publication date
CN118976023A (zh) 2024-11-19
WO2020146529A1 (en) 2020-07-16
JP2022516662A (ja) 2022-03-01
US20220142977A1 (en) 2022-05-12
EP3908276B1 (en) 2025-06-11
CA3124701A1 (en) 2020-07-16
AU2020206700A1 (en) 2021-07-15
CN113874009A (zh) 2021-12-31
EP3908276A1 (en) 2021-11-17
IL284114A (en) 2021-08-31
KR20210113298A (ko) 2021-09-15

Similar Documents

Publication Publication Date Title
MX2021008263A (es) Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.
CO2021008817A2 (es) Compuesto agonista de receptor thrβ y método de preparación y uso del mismo
ZA202206923B (en) New methylquinazolinone derivatives
CL2021002903A1 (es) Inhibidores de cdk
ECSP21000990A (es) Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteína con dedos de zinc 2 de la familia ikaros (ikzf2)
EP4349840A3 (en) Pyrazolopyridine derivative having glp-1 receptor agonist effect
CL2022000666A1 (es) Compuesto de piridona fusionada y método de preparación del mismo y uso del mismo
AR114803A1 (es) Compuestos de 4-aminoisoindolin-1,3-diona sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos
ZA202006378B (en) N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof
MX2021014508A (es) Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
ECSP22092977A (es) Antagonista del receptor crf1 para el tratamiento de la hiperplasia suprarrenal congénita
MX2009001660A (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis.
MX2021007258A (es) Composiciones de esparsentan amorfas.
BR112018075206A2 (pt) tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
CO6361991A2 (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos.
CO2021002768A2 (es) Compuestos de 2,6-diaminopiridina
WO2016205738A3 (en) Delivery systems for controlled drug release
MX2017007607A (es) Inhibidores de necrosis celular y metodos relacionados.
AR103412A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
MY190849A (en) Methods of treating multiple sclerosis
CO2023007882A2 (es) Compuesto heterocíclico aromático, y composición farmacéutica y aplicación de estos
ECSP20066271A (es) Derivados de pirazo-tetrahidroisoquinolina como moduladores positivos del receptor de dopamina d1
EA201692298A1 (ru) Производные карбоксамидов
EA201891682A1 (ru) Производное азациклического амида, способ его получения и фармацевтическое применение
PH12021552953A1 (en) Tricyclic compounds